EVENTS | VIEW CALENDAR
KineMed and Pfizer to advance novel approaches in metabolic disease
EMERYVILLE, Calif.—KineMed Inc. announced last month a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular type 2 diabetes.
The collaboration will employ KineMed's Dynamic Proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
Financial details of the collaboration were not released.
"We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets," stated Dr. Scott Turner, executive vice president of R&D at KineMed. "We are using our translational platform to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials."
Diabetes is an increasingly challenging global healthcare problem and in the United States affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations, and new cases of blindness among adults in the United States.
Despite more than 50 years of drug research, more than 60 percent of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.